Mark Wildgust (he/him) (@MAWildgust) header
Mark Wildgust (he/him) (@MAWildgust) profile picture

VP of Oncology Global Medical Affairs at Johnson & Johnson, focused on bringing new treatment options for pts with cancer. Tweets/views shared are my own

Raritan, NJ
Joined February 2018
Photo by Mark Wildgust (he/him) (@MAWildgust)Photo by Mark Wildgust (he/him) (@MAWildgust)Photo by Mark Wildgust (he/him) (@MAWildgust)Photo by Mark Wildgust (he/him) (@MAWildgust)Photo by Mark Wildgust (he/him) (@MAWildgust)Photo by Mark Wildgust (he/him) (@MAWildgust)Photo by Mark Wildgust (he/him) (@MAWildgust)Photo by Mark Wildgust (he/him) (@MAWildgust)Photo by Mark Wildgust (he/him) (@MAWildgust)Photo by Mark Wildgust (he/him) (@MAWildgust)
At #ESMO26 we introduced a new word, #RIPTAC, JNJ-6143. Introducing another innovation presented @sitcancer yesterday! FIH Investigational combo of Pasritamig our @JNJInnovMed KLK2xCD3 T-cell agent + our PSMA x CD28 co-stim JNJ-9401. Signal 1 & signal 2 together! #MyCompany
6
27
1
81
8,230
Slides available here.
1
258
Phenomenal job Dr Graham in presenting these data!!
1
6
406
Mark Wildgust (he/him) retweeted
7. COCOON: Supportive care & Dermatologic management for Amivantamab + Laz in NSCLC: - Derm prophylaxis cuts Gr≥2 derm AEs ~75% to 42%. - SubCutaneous Ami + simplified regimen: Gr≥2 by wk12 39% to 18% w/ Laz lead-in. - ⬇️ discontinuations and improve tolerability. 9/10
The speed at which COCOON is rewriting the story of EGFR treatment is extraordinary! Grade ≥2 AEs: 75% → 42%. Now, early data with simplified prophylaxis + lazertinib lead-in: 39% → 18%. Not just managing toxicity. Changing its trajectory. #ESMO26 #LungCancer
1
3
5
833
Delighted to share the publication of the Proteus sub-study today in @EUplatinum. Wonderful complement to the presentation here at #ESMO2026. #MyCompany sciencedirect.com/science/ar…
3
10
474
A targeted dual-protein lock. A completely new way of thinking about cancer therapy. #JNJ6143 is a first-in-class #RIPTAC™ oral small molecule designed to selectively bring together two proteins—AR and BRD4—inside prostate cancer cells, creating a ternary complex that disrupts cancer-driving biology and triggers tumor cell death. @BGarmezy showcased this at #ESMO2026 today and it has been the talk of the meeting! #ProstateCancer #Oncology #CancerResearch #PrecisionMedicine
3
16
1
49
2,865
Great to see @cbcbc1971 present these data here at #ESMO2026. @jillfeldman4 @AlexSpiraMDPhD and many others have been such leaders. These COCOON data represent the “Modern MARIPOSA” regimen.
Replying to @myESMO
@myesmo #ESMO26 #lung 🫁 #rapidorals on going! #BCCho from @yonsei_u presented on modified run-in strategies in improving prevention of cutaneous s/e in Ami_Laz with new #COCOON regimen. #LCSM #drugdevelopment #ESMOAmbassadors
4
3
441
Thrilled for @BGarmezy to present updated results for JNJ-6143. @JNJInnovMed team are excited about these results and the potential to provide patients with more tomorrows and better today’s. Exciting MOA, “first in class molecule”. #esmo26 #mycompany
Thrilled to share updated results from JNJ-6143, the AR-BRD4 RIPTAC therapy, presented by @BGarmezy. Totally novel MOA was well tolerated, oral pill and produced significant benefit for pts (PSA90 50%, ORR 68%). P2 trial active now and more coming. Lots of potential!
1
5
1
21
1,894
Thank you @APassaroMD. The @JNJInnovMed team are focused on supporting patients with better today’s and more tomorrows. Congratulations @cbcbc1971 and @LeXiuning for presentation and discussion. #ESMO2026
The speed at which COCOON is rewriting the story of EGFR treatment is extraordinary! Grade ≥2 AEs: 75% → 42%. Now, early data with simplified prophylaxis + lazertinib lead-in: 39% → 18%. Not just managing toxicity. Changing its trajectory. #ESMO26 #LungCancer
4
353
Delighted to see @cbcbc1971 share new #COCOON results, two new cohorts, a simplified COCOON DM regimen and new Lazertinib first run in! #ESMO26. #MyCompany
For US HCPs at the 2026 ESMO Congress: Watch @cbcbc1971 (Dr. Byoung Chul Cho) present first results from a new COCOON cohort evaluating subcutaneous amivantamab (SQ AMI) in patients with EGFR-mutant advanced NSCLC.​ Discover findings from the first COCOON cohort using SQ AMI, including a new Simplified Regimen and staggered treatment initiation strategies aimed at reducing moderate to severe dermatologic adverse events.​ Click here for more details:​ congresshub.com/Oncology/ESM…​ ​ #NSCLC #HCP #ESMO26
5
316
Mark Wildgust (he/him) retweeted
Walter payton
Winnie the Pooh isn’t available, who’s the greatest bear of all time?
1
1
97
I was humbled to speak at #IMS26 today about the path @JNJInnovMed has been charting towards #cure. I shared the five-step formula we are using, based on our former R&D head Peter Lebowitz. We are humbled to be a member of the community working shoulder-to-shoulder towards this goal. #MyCompany
1
2
32
1,050
Mark Wildgust (he/him) retweeted
Incredible 2-year PFS with Ramantamig in a ~95% CD38-refractory and 100% triple-class exposed population! These results are substantially superior compared to single-agent BCMA BsAbs and BCMA or GPRC5D CAR Ts in similar population. Based on these results, its plausible that we will see a near-flat PFS curve with Ram in Trilogy-5! #IMS26 @AlGarfall @MileHighMyeloma
1
31
3
99
7,034
Excited to be presenting here at #IMS26 tomorrow in the session entitled "Future Targets and New Modalities of Therapy". @SagarLonialMD and Kwee Yong are chairs. Hall 5, 9:30-10:20am. I'll share the 5-step formula @JNJInnovMed has been following towards #cure.
1
6
18
773
I am raising money for @BloodCancerUtd Light the Night Event November 7th. There is a unique matching funds opportunity right now! Donate: pages.lls.org/ltn/snj/Mercer… If you are able, please can you sponsor me and support this incredible organization. #BloodCancer #LighttheNight
152
#Hope is one of the most powerful medicines we can offer. That is why I am horned and humbled to be serving as the 2026 Corporate Walk Chair for Light The Night Mercer County on Nov 7. Over the years, I’ve seen firsthand the power of this event – the families finding hope, communities coming together, and supporters rallying behind a cause that impacts so many lives.  #LightTheNight is an event where communities come together to carry lanterns and honor those affected by blood cancer—raising funds for @BloodCancerUtd New Jersey mission to advance research, advocacy, and patient support. It would mean a lot to me to have your support by donating to this great event: pages.lls.org/ltn/snj/Mercer… I’m looking forward to working with our amazing volunteers, sponsors, and community leaders to make this year our most impactful yet. Whether you join us as a walker, fundraiser, sponsor, or volunteer, there’s a place for you on this journey. Thank you, in advance, and let’s light the night together! Thank you for standing with the blood cancer community. Together, we can bring light, hope, and progress to those who need it most. #LightTheNight #HopeInAction #BloodCancerUnited #CancerResearch #Oncology #PatientAdvocacy #Leadership
1
1
6
640
Mark Wildgust (he/him) retweeted
#Myeloma Paper of the Day: Teclistamab-based induction in TE NDMM shows MRD- CR rate 91.8% (45/49) by pre-maintenance timepoint, 100% in evaluable samples & post-induction cycle 3 (10-5 (46/46)), 6 (10-5 (46/46) & 10-6 (46/46)); ORR was 100%: pubmed.ncbi.nlm.nih.gov/4235…. #mmsm
2
28
3
46
9,005